top of page


Brazil hospital doctor salaries reach R$12,974 per month in new 2026 recruitment figures
Newly published Brazilian hospital recruitment data reveal monthly basic salaries of up to R$12,974.40 for physicians across a range of medical specialties, providing a fresh November 2026 benchmark for hospital doctor compensation.

nuaxia
1 hour ago3 min read


Helus Pharma reports positive Phase III HLP003 results in major depressive disorder
Helus Pharma has reported positive Phase III results for investigational deuterated psilocin treatment HLP003 in major depressive disorder, with statistically significant improvements in depression scores through 12 weeks.

nuaxia
2 hours ago2 min read


FDA approves Teva's Igalmi for at-home treatment of acute agitation in adults with schizophrenia or bipolar disorder
The FDA has expanded the authorised use of Teva's Igalmi sublingual film to at-home treatment of acute agitation associated with schizophrenia, schizoaffective disorder and bipolar disorder, introducing a new outpatient treatment setting.

nuaxia
2 hours ago2 min read


FDA approves Klygefa gefurulimab for adults with AChR-positive generalised myasthenia gravis
The FDA has approved Klygefa, a weekly subcutaneous complement inhibitor, for adults with acetylcholine receptor antibody-positive generalised myasthenia gravis, adding another targeted treatment option for this autoimmune neuromuscular disorder.

nuaxia
2 hours ago2 min read


Eli Lilly agrees to acquire Calytrix Bio for up to $1.5 billion to expand rare blood cancer pipeline
Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion, adding a preclinical antibody programme targeting mutant calreticulin in rare myeloproliferative blood disorders.

nuaxia
2 hours ago2 min read


Johnson & Johnson agrees to acquire Ollin Biosciences for up to $3.3 billion to expand retinal disease pipeline
Johnson & Johnson has agreed to acquire ophthalmology biotechnology company Ollin Biosciences for up to approximately $3.3 billion, adding a Phase III retinal disease antibody programme alongside a separate $750 million Blackstone development funding arrangement.

nuaxia
2 hours ago2 min read


European Commission approves Revolution Medicines' Rasonque as first broad RAS-targeted therapy for metastatic pancreatic cancer
The European Commission has authorised Revolution Medicines' Rasonque as an oral broad RAS-targeted treatment for previously treated metastatic pancreatic cancer, marking a significant advance in a disease with substantial unmet medical need.

nuaxia
2 hours ago2 min read


FDA approves Roche's Gazyva as first specifically authorised treatment for primary membranous nephropathy
The FDA has approved Roche's Gazyva for primary membranous nephropathy, establishing the first specifically authorised treatment for the condition after Phase III evidence demonstrated substantially higher complete proteinuria remission rates than tacrolimus.

nuaxia
2 hours ago2 min read


FDA approves Roche's Wilserdly with everolimus for ESR1-mutated advanced breast cancer
Roche's oral selective oestrogen receptor degrader Wilserdly has received FDA approval alongside everolimus for eligible patients with ESR1-mutated advanced breast cancer, supported by Phase III evidence of reduced disease progression risk.

nuaxia
2 hours ago2 min read


German doctors secure 5.4% salary increase under new Berlin hospital pay agreement
Physicians at Berlin's Charité university hospital are set to receive a 5.4% salary increase under a new collective bargaining agreement, with enhanced shift allowances potentially bringing the overall value of the package to 7.15%.

nuaxia
1 day ago4 min read


Sandoz launches Enzeevu aflibercept biosimilar in US with new private-label distribution agreement
Sandoz has launched its interchangeable aflibercept biosimilar Enzeevu in the United States and announced a multi-year private-label distribution arrangement, expanding commercial competition in treatments for retinal vascular diseases.

nuaxia
1 day ago2 min read


OBI Pharma signs ADC platform licensing agreement with Novartis worth more than $2 billion
OBI Pharma has entered a global antibody-drug conjugate platform licensing agreement with Novartis carrying more than $2 billion in potential value, including a $30 million upfront payment and additional contingent milestones and royalties.

nuaxia
1 day ago2 min read


CHMP recommends Innovent's Zybrivo sintilimab for first-line non-squamous lung cancer in Europe
The EMA's CHMP has recommended Innovent's Zybrivo, containing sintilimab, for first-line treatment of eligible patients with non-squamous non-small cell lung cancer, advancing the immunotherapy towards a potential European marketing authorisation.

nuaxia
1 day ago2 min read


FDA approves Biocon's Pebrilzo pertuzumab biosimilar for HER2-positive breast cancer
Biocon has secured US FDA approval for Pebrilzo, a pertuzumab biosimilar for HER2-positive breast cancer, expanding its oncology biosimilar portfolio while commercial entry remains subject to a patent settlement allowing launch from the third quarter of 2028.

nuaxia
1 day ago2 min read


FDA declines approval of Summit and Akeso's ivonescimab for EGFR-mutated lung cancer
The FDA has issued a Complete Response Letter for Summit Therapeutics' ivonescimab in EGFR-mutated lung cancer after the HARMONi trial demonstrated a progression-free survival benefit but did not establish a statistically significant overall-survival benefit.

nuaxia
1 day ago2 min read


FDA requires new NAION vision-loss risk warnings across GLP-1 receptor agonist medicines
The FDA has ordered class-wide labelling changes for GLP-1 receptor agonists following evidence of a potential association with rare but potentially permanent vision loss caused by non-arteritic anterior ischaemic optic neuropathy.

nuaxia
4 days ago2 min read


UK MHRA approves Incyte's Zynyz for advanced anal cancer as NICE backs NHS access
The UK MHRA has authorised Incyte's Zynyz with carboplatin and paclitaxel for advanced anal cancer, accompanied by a positive NICE access recommendation and Phase III evidence of improved median overall survival.

nuaxia
4 days ago2 min read


Pfizer and Blackstone agree up to $1.5 billion in development funding for monthly GLP-1 obesity candidate berobenatide
Pfizer and Blackstone Life Sciences have agreed a development co-funding arrangement of up to $1.5 billion for investigational once-monthly GLP-1 therapy berobenatide, sharing clinical development risk while Pfizer retains control of the programme.

nuaxia
4 days ago2 min read


European Commission expands Oncopeptides' Pepaxti authorisation to third-line multiple myeloma
The European Commission has approved an expansion of Oncopeptides' Pepaxti label into third-line multiple myeloma treatment, broadening eligibility after two prior lines of therapy and removing the previous triple-class refractory requirement.

nuaxia
4 days ago2 min read


PharmaLogic agrees to acquire Lantheus radiopharmaceutical CDMO business and New Jersey manufacturing facility
PharmaLogic has signed a definitive agreement to acquire Lantheus' radiopharmaceutical CDMO operations and Springfield manufacturing facility, expanding specialist production capabilities for therapeutic radiopharmaceuticals.

nuaxia
4 days ago2 min read
bottom of page